Although routine p53 IHC will incur higher cost than histological assessment alone, application of this marker has the potential to reduce the overall costs related to BE surveillance by improved risk stratification using expression of p53 IHC in combination with other predictors of progression, such as histology, sex, age, and length of the BE segment. Here, TP53 is linked to Barrett esophagus.